ROIV News and Press, Roivant Sciences Ltd. From 01/04/23

RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested Across all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively. Similar results were observed at the expected Phase 3 dose ...

Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...

Summary Roivant's differentiated approach to the drug development business has been hit and miss. The company's subsidiary Dermavant won a first approval this year for Vtama cream - indicated for plaque psoriasis. A follow-up approval in Atopic Dermatitis opens up an intriguing, pot...

Roivant Sciences ( NASDAQ: ROIV ) said it will be part of a $21M investment round being led by Edison Partners in clinical trial intelligence company Lokavant. Lokavant will use the funds to scale its commercial teams, and boost feature development for its platform, whic...

Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant PR Newswire Investment will transform the clinical research industry for smarter and faster trials PRINCETON, N.J. and NEW YORK , Dec. 7, 2022 /PRNewswire/ ...

Shares of Roivant Sciences (NASDAQ: ROIV) were up more than 10% on Thursday. The stock closed on Wednesday at $5.36, then opened on Thursday at $5.75. The stock got as high as $5.92 shortly after 2 p.m. ET. It has a 52-week high of $16.76 and a 52-week low of $2.52. Roivant stock is down ...

Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis RVT-3101 is currently being evaluated in a large global Phase...

Roivant Sciences Ltd. (ROIV) Q2 2022 Earnings Conference Call November 14, 2022, 8:00 am ET Company Participants Jeffrey Kalmus - Head, Strategic Finance Matt Gline - CEO Conference Call Participants David Risinger - SVB Securities Brian Cheng - J.P. ...

Roivant Sciences press release ( NASDAQ: ROIV ): Q2 GAAP EPS of -$0.42 misses by $0.01 . Revenue of $12.53M (-10.4% Y/Y) beats by $6.83M . As of September 30, 2022, we had cash, cash equivalents and restricted cash of approximately $1.6 billion. For furth...

Expected cash runway extended into the second half of calendar year 2025 First major PBM/payer contract signed for VTAMA, effective October 1 Over 54,000 VTAMA prescriptions written by approximately 6,400 prescribers since launch show strong demand, with fiscal Q2 2022 n...